Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer

NCT01196247 is registered in ClinicalTrials.gov with Translational Drug Development as lead sponsor.

NCT NCT01196247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01196247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer
Lead sponsor
Translational Drug Development
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
February 29, 2012
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated metastatic pancreatic cancer